The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma

BACKGROUND: Sorafenib is the drug of choice in the treatment of advanced hepatocellular carcinoma (HCC). Beneficial effects are limited by mechanisms of chemoresistance, which include downregulation and/or impaired function of plasma membrane transporters accounting for drug uptake. The organic cati...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Geier, Andreas, Macias, Rocio I.R., Bettinger, Dominik, Weiss, Johannes, Bantel, Heike, Jahn, Daniel, Al-Abdulla, Ruba, Marin, Jose J.G.
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2017
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5362528/
https://ncbi.nlm.nih.gov/pubmed/28178663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15029
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares